Literature DB >> 30718124

Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.

Pierre Vassilakos1, Antoine Poncet2, Rosa Catarino3, Manuela Viviano4, Patrick Petignat4, Christophe Combescure2.   

Abstract

OBJECTIVE: About 30% of women who are eligible for cervical cancer (CC) screening remain un-screened or under-screened in Switzerland. HPV testing on self-collected vaginal samples (Self-HPV) has shown to be more sensitive than cytology while also reaching non-attendees. The objective of this study was to explore the cost-effectiveness of offering Self-HPV to non-attendees in Switzerland.
METHODS: A recursive decision-tree with one-year cycles was used to model the life-long natural HPV history. Markov cohort simulations were used to assess the expected outcomes from the model. The outcomes of three strategies were compared with the absence of screening: Self-HPV and triage with colposcopy (Self-HPV/colpo), Self-HPV and triage with Pap cytology (Self-HPV/PAP), cytological screening and triage with HPV (PAP/HPV). Sensitivity analyses for the key parameters of the model were conducted to check the robustness of findings.
RESULTS: Offering a Self-HPV screening to non-attendees could prevent 90% of CC and 94% of CC-related deaths in the study population. The current cytology-based program could reduce by 83% the number of CC cases and by 88% the number of CC-related deaths over the population's lifetime. Compared to the absence of screening, incremental cost-effectiveness ratios (ICER) were estimated to be, per saved Quality Adjusted Life Year (QALY), 12413US$ for the strategy Self-HPV/colpo, 11138US$ for the strategy Self-HPV/Pap and 22488US$ for the strategy PAP/HPV.
CONCLUSIONS: Offering Self-HPV as a CC screening strategy to non-attendees in Switzerland is a cost-effective solution that is associated with a reduction of CC cases and related deaths. Self-HPV is more cost-effective than the currently used cytology-based screening.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer screening; Cost-effectiveness; Developed countries; Self-HPV; Switzerland

Mesh:

Year:  2019        PMID: 30718124     DOI: 10.1016/j.ygyno.2019.01.021

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Cost-effectiveness studies of HPV self-sampling: A systematic review.

Authors:  Colin Malone; Ruanne V Barnabas; Diana S M Buist; Jasmin A Tiro; Rachel L Winer
Journal:  Prev Med       Date:  2020-01-03       Impact factor: 4.018

2.  Cost-effectiveness analysis of repeated self-sampling for HPV testing in primary cervical screening: a randomized study.

Authors:  Riina Aarnio; Ellinor Östensson; Matts Olovsson; Inger Gustavsson; Ulf Gyllensten
Journal:  BMC Cancer       Date:  2020-07-13       Impact factor: 4.430

3.  Clinical performance and acceptability of self-collected vaginal and urine samples compared with clinician-taken cervical samples for HPV testing among women referred for colposcopy. A cross-sectional study.

Authors:  Dorthe Ørnskov; Kirsten Jochumsen; Pernille Husted Steiner; Ivan Moulun Grunnet; Annemette Wildfang Lykkebo; Marianne Waldstrøm
Journal:  BMJ Open       Date:  2021-03-05       Impact factor: 2.692

4.  Harms and benefits of cervical cancer screening among non-attenders in Switzerland: The transition towards HPV-based screening.

Authors:  Rosa Catarino; Pierre Vassilakos; Patrick Petignat; Christophe Combescure
Journal:  Prev Med Rep       Date:  2022-07-30

5.  A systematic review of economic evaluations of cervical cancer screening methods.

Authors:  Thatohatsi Sefuthi; Lungiswa Nkonki
Journal:  Syst Rev       Date:  2022-08-09

6.  The Cost-Effectiveness Analysis of Cervical Cancer Screening Using a Systematic Invitation System in Lithuania.

Authors:  Justina Paulauskiene; Mindaugas Stelemekas; Rugile Ivanauskiene; Janina Petkeviciene
Journal:  Int J Environ Res Public Health       Date:  2019-12-11       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.